10-Q: Network-1 Gains $1.05M from ILiAD and Wins Google Appeal

Network-1 Technologies reported a non-cash gain on its biotechnology investment and a significant appellate victory in its patent litigation against Google.

Summary

• Reported zero revenue for the quarter ended March 31, 2026, compared to $150,000 in the first quarter of 2025.
• Realized a net loss of $511,000, or $0.02 per share, compared to a net loss of $363,000 in the prior year period.
• Recognized a $1,052,000 gain on an equity investment in ILiAD Biotechnologies following its $115 million Series B financing.
• Maintains a strong liquidity position with $34,589,000 in cash, cash equivalents, and marketable securities.
• Operating expenses increased to $1,415,000 from $795,000, driven by a $625,000 rise in litigation-related professional fees.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a transition quarter where poor financial results are offset by major legal catalysts, specifically the Google appeal win and the Samsung PTAB victory.

Positives

• The U.S. Court of Appeals for the Federal Circuit overturned a non-infringement judgment regarding the '237 patent in the Google/YouTube litigation, remanding the case for further proceedings.
• The U.S. Patent Trial and Appeal Board denied six Inter Partes Review proceedings requested by Samsung, protecting all six asserted patents in the M2M/IoT portfolio.
• ILiAD Biotechnologies successfully completed a $115 million financing round, validating the value of the company's 2.5% fully diluted stake.
• Maintained a semi-annual cash dividend of $0.05 per share, demonstrating a commitment to shareholder returns despite current losses.

Negatives

• Generated no revenue from licensing activities during the three months ended March 31, 2026.
• Professional fees and litigation costs surged by $654,000 year-over-year as active cases progressed toward trial.
• Recorded $287,000 in realized and unrealized losses on marketable securities due to declining market values of fixed-income holdings.
• The company's ownership in ILiAD was diluted to 2.5% following the Series B financing.

Risks

• Revenue is highly dependent on the unpredictable outcomes of patent litigation and the ability to secure new license agreements.
• Potential classification as a Personal Holding Company in 2026 could result in a 20% tax on undistributed income.
• The company has ceased monetization of its Remote Power and Mirror Worlds patent portfolios, limiting active income sources to four remaining portfolios.
• Future operating results are expected to fluctuate significantly based on the timing of legal settlements and court rulings.

Future Outlook

Future revenue is entirely dependent on the successful monetization of the M2M/IoT, HFT, Cox, and Smart Home patent portfolios. Management is actively seeking to acquire additional high-quality patents and explore strategic relationships to generate new licensing opportunities.

Management Comments

• The company's strategy focuses on acquiring high-quality patents with potential for significant licensing opportunities.
• The Compensation Committee is currently discussing terms for a new employment agreement with the Chairman and CEO.

Industry Context

StockSavvy.ai notes that Network-1 operates as a patent assertion entity, a business model characterized by highly volatile, 'lumpy' revenue tied to the legal system rather than traditional product cycles. The recent appellate win against Google is a significant industry event, as it revives a high-stakes claim against a major tech incumbent.

Comparison to Industry Standards

• Maintains a robust cash-to-expense ratio compared to other micro-cap intellectual property firms, allowing for prolonged litigation cycles.
• The 2.5% stake in a well-funded clinical-stage biotech (ILiAD) provides a unique diversification asset not typically found in pure-play patent licensing companies.
• Legal success rates at the PTAB and Federal Circuit are currently tracking above industry averages for patent assertion entities.

Corporate Governance

Legal Proceedings

• Federal Circuit overturned a non-infringement judgment in the Cox Patent Portfolio litigation against Google.
• PTAB denied Samsung's requests for Inter Partes Review on six M2M/IoT patents.
• Ongoing litigation against Optiver, Citadel, and Jump Trading regarding the HFT Patent Portfolio.

Related Party Transactions

• Dr. Cox is entitled to 12.5% of net proceeds from the Cox Patent Portfolio.
• The CEO previously held a board seat at ILiAD Biotechnologies.

Stakeholder Impact

• Shareholders continue to receive a steady dividend yield despite the lack of current revenue.
• Legal teams remain the primary beneficiaries of current cash outflows as litigation intensifies.

Next Steps

• Proceed with remanded patent infringement litigation against Google in the District Court.
• Prepare for trials against Samsung and Optiver scheduled for June 2027.
• Continue share repurchases under the remaining $4,827,750 authorization.

Key Dates

Recommendation

While the current lack of revenue is a concern, the company's massive cash pile and recent legal victories against Google and Samsung provide significant asymmetric upside potential that warrants holding the position for trial outcomes.

Keywords

Intellectual Property, Patent Litigation, Licensing Revenue, M2M/IoT, High Frequency Trading, Biotechnology Investment, Share Repurchase, Dividends